Low-grade serous ovarian cancer: State of the science.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
03 2020
Historique:
received: 29 10 2019
revised: 18 12 2019
accepted: 23 12 2019
pubmed: 24 1 2020
medline: 3 7 2020
entrez: 24 1 2020
Statut: ppublish

Résumé

In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.

Identifiants

pubmed: 31969252
pii: S0090-8258(19)31862-1
doi: 10.1016/j.ygyno.2019.12.033
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

715-725

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Overall, there are no conflicts of interest with regard to this article (individual COI are disclosed on COI forms).

Auteurs

Brian Slomovitz (B)

Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States. Electronic address: bslomovitz@med.miami.edu.

Charlie Gourley (C)

Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, UK.

Mark S Carey (MS)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.

Anais Malpica (A)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Ie-Ming Shih (IM)

Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

David Huntsman (D)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Amanda N Fader (AN)

Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Rachel N Grisham (RN)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weil Cornell Medical College, New York, NY, United States.

Matthew Schlumbrecht (M)

Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

Charlotte C Sun (CC)

Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Jane Ludemann (J)

Cure Our Ovarian Cancer, cureourovariancancer.org, New Zealand.

Gail Austin Cooney (GA)

University of Miami/JFK Medical Center Palm Beach Regional Graduate Medical Education Consortium, Hospice and Palliative Medicine Program, West Palm Beach, FL, United States.

Robert Coleman (R)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Anil K Sood (AK)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Haider Mahdi (H)

Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, OH, United States; Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States.

Kwong K Wong (KK)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Allan Covens (A)

University of Toronto, Division of Gynecologic Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

David M O'Malley (DM)

Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, The James CCC at the Wexner Medical Center-The Ohio State University College of Medicine, Columbus, OH, United States.

Fabrice Lecuru (F)

Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen George Pompidou, APHP, Paris, France; Faculté de Médecine, Université Paris Descartes, Paris, France.

Lauren P Cobb (LP)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Thomas A Caputo (TA)

Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, United States.

Taymaa May (T)

Division of Gynecologic Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.

Marilyn Huang (M)

Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

John Siemon (J)

Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

Marta Llauradó Fernández (ML)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.

Isabelle Ray-Coquard (I)

Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire (GINECO), Lyon, France.

David M Gershenson (DM)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH